anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
NEW MATERIAL:An aminoglycoside shown by the formula I (R1 and R2 are H, or CH3; R3 is H, glycyl, or formimidoylglycyl; X1 and X2 are H, or F, with the proviso that X1 and X2 are not H simultaneously) and its salt. EXAMPLE:3-Epifluoro-3-demethoxysporaricin A tetrahydrochloride. USE:Having low toxicity, an improved antimicrobial agent. PROCESS:A compound shown by the formula II (R3&#39;&#39; is H, or acyl; A and B are H, OH, or linked to form oxo) or a compound obtained by protecting the NH2 and/or OH at 5-position of the compound is fluorinated, and, if necessary, methylamino at 4-position is converted into glycyl or formimidoylglycyl, and the reaction product is processed into an acid addition salt to give a compound shown by the formula I . The fluorination is preferably carried out in a solvent such as benzene, etc. using a fluorinating reagent such as dimethylaminosulfo trifluoride, etc. after the NH2 and OH at 5-position are protected.
Prescription opioids remain a popular drug class with 143 million (M) opioid prescriptions written in 2020. In that same year, 8.7 million people (2.6% of the US population) misused prescription pain relievers, and overdose deaths from opioids continue to rise to 83,695 in 2022. Across six studies, 67% to 92% of patients prescribed opioids reported unused pills. In 2017, patients were prescribed 3.3 billion excess pills, yet no more than 9% of patients properly disposed of their unused opioids. Despite attempts to reduce overprescribing, increase disposal, and decrease diversion, these issues still contribute to increasing misuse, addiction, and overdose deaths.

Addinex Technologies has developed a novel system to reduce the use of opioids through controlling, monitoring, and disposing of excess opioids. The unique "closed-loop" system starts with clinicians prescribing opioids with the Addinex system. Addinex's partner pharmacy then fills the patented dispenser and delivers it to the patient. The patient uses the Addinex app to access each individual dose code and to obtain education and feedback. Finally, the patient returns the dispenser with any excess pills in a DEA-approved mailer to Addinex's partner disposal company. In a study with Columbia University Medical Center using the Addinex system with 30 post-surgical cancer patients, results showed 70% fewer pills used than prescribed, 60% fewer refills for the same surgeries, and an 84% excess pill disposal rate.

Addinex is now partnering with Brown Emergency Medicine and Rhode Island Hospital ("Brown") to perform a feasibility study using Addinex\&#39;s system. We will conduct a clinical trial involving 100 patients with extremity fractures treated by the emergency department. Half the patients (25 adults and 25 minors) will utilize the Addinex system, while the other half will have their opioids dispensed in a standard pill bottle as the control group. Addinex's system promotes the return of medication using a pre-paid disposal mailer once patients have completed their course of treatment. The clinical study\&#39;s main goals involve evaluating the system\&#39;s effectiveness with patients obtaining same day treatment. This evaluation will encompass an analysis of medication consumption, disposal rates, pain levels, the impact of monitoring policies, and ensuring that the established commercial protocols function seamlessly. Ultimately, the project aims to demonstrate that the Addinex system can successfully operate within the broader hospital environment (same day and scheduled procedures), controlling and monitoring opioid usage, promoting patient well-being, and lowering costs.
The present invention discloses a drug for promoting the production of body liquid and treating diarrhea, which has a formula according to components and parts by weight: 5 to 6 portions of codonopsis pilosula, 5 to 10 portions of stir-fried atractylodes macrocephala, 1 to 5 portions of poppy capsule, 6 to 15 portions of Chinese yam, 5 to 10 portions of black plum, 6 to 15 portions of white hyaciath bean, 6 to 15 portions of stir-fried coix seed, 3 to 10 portions of euryale seed, 6 to 10 portions of white tuckahoe, 3 to 10 portions of chicken&#39;s gizzard, 7 to 15 portions of white lotuses and 2 to 5 portions of glycyrrhiza. The drug for promoting the production of body liquid and treating diarrhea is used for spleen righting invigoration, body liquid production and diarrhea treatment, and mainly treats diseases, such as infant enteritis diarrhea, dyspepsia diarrhea, infant spirit tiredness caused by the diarrhea, water insufficiency caused by the diarrhea, etc. The present invention has the functions of body liquid production, diarrhea treatment and spleen righting invigoration. The drug for promoting the production of body liquid and treating diarrhea not only can treat superficial diseases, but also can treat root diseases. The drug is a pure traditional Chinese drug tablet and powder cooked into liquid for oral administration. The drug for promoting the production of body liquid and treating diarrhea has the advantages of no toxic or side effect, low cost and rapid treatment, a sick infant does not need to stay in hospital and take an injection, and the pain of the sick infant and parents is reduced. The sick infant can recover by treatment only from 3 to 5 days by costing tens of yuan.
FIELD: medicine; pharmaceuticals.SUBSTANCE: what is offered is a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, losing weight, reducing blood sugar, reducing lipids, inhibiting appetite in a subject, reducing the total serum cholesterol level and/or reducing the triglyceride content in the liver, its version, the composition and use of said compositions. Said pharmaceutical composition contains a pharmaceutically effective amount of a GLP-1 receptor agonist and a glucagon receptor agonist. GLP-1 receptor agonist and the glucagon receptor agonist each independently form a conjugate with a hydrophilic polymer, a molar ratio of the conjugate, including a GLP-1 receptor agonist, to a conjugate comprising a glucagon receptor agonist ranges from 1:1 to 1:15. In the above composition, the GLP-1 receptor agonist is selected from exendin-4, exendin-3 and GLP-1, and the glucagon receptor agonist is glucagon and the hydrophilic polymer is polyethylene glycol. Variant of the pharmaceutical composition comprises an agent selected from a group consisting of: a combination of PB-721 and PB-119, a combination of PB-722 and PB-119 and a combination of PB-708 and PB-120, where PB-721 is mPEG-23KD-ppMAL-PB-740, where PB-740 has an amino acid sequence SEQ ID NO: 5; PB-722 is mPEG-23KD-ppMAL-PB-741, where PB-741 has the amino acid sequence SEQ ID NO: 6, in which the &#34;-CO-NH&#34; side chain of glutamine in 24 position is modified in &#34;-CO-NH-CHCH-SH&#34;; PB-119 is mPEG-23KD-ppMAL-PB-105, where PB-105 has the amino acid sequence SEQ ID NO: 1; PB-120 is mPEG-25KD-ppMAL-PB-105, where PB-105 has the amino acid sequence SEQ ID NO: 1; and PB-708 is mPEG-25KD-ppMAL-PB-703, where PB-703 has the amino acid sequence SEQ ID NO: 4. What is also presented is a kit for preventing or treating non-alcoholic fatty liver disease, losing weight, reducing blood sugar, lowering lipids, inhibiting appetite in the individual, reducing total serum cholesterol and/or reducing triglycerides in the liver, comprising the composition.EFFECT: composition and variant thereof can be used for preparing a drug for preventing or treating non-alcoholic fatty liver disease, losing weight, reducing lipids and/or reducing blood sugar, as well as for preparing a drug for suppressing appetite in a subject, reducing the level of total cholesterol in the serum and/or reducing the content of triglycerides in the liver.11 cl, 40 dwg, 3 tbl, 21 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a food containing viable lactic acid bacteria, needing neither costly process nor material and efficiently deliverable to the intestine through its oral administration.  &lt;P&gt;SOLUTION: A nucleic acid complex for protecting viable lactic acid bacteria from gastric juice comprising a nucleic acid, one or more gelatinizers and water is provided. A nucleic acid complex mixture with viable lactic acid bacteria protected therein comprising said nucleic acid complex and an emulsified product prepared by emulsifying a liquid containing the viable lactic acid bacteria with an emulsifier and fat and oil is provided. A method for producing said nucleic acid complex mixture comprises mixing said emulsified product with said nucleic acid complex. A method for protecting lactic acid bacteria from gastric juice is also provided. In the above, the nucleic acid complex is preferably such one that the nucleic acid is a DNA derived from living body waste in particular and the gelatinizer(s) comprises gelatin and carrageenan. Further, said emulsifier and oil and fat preferably comprise lecithin and cacao butter respectively.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a preparation method of N,N-dialkyl polyhydroxyalkyl amine, and a method of its use.  &lt;P&gt;SOLUTION: The N,N-dialkyl polyhydroxyalkyl amine can be prepared through reductive alkylation of N-alkyl polyhydroxyalkyl amine and an aldehyde, a ketone or a compound equivalent to these in the presence of a transition metal catalyst and hydrogen. The reaction is carried out in a reaction solvent containing at least 30 wt.% organic solvent. A sufficiently high proportion of an appropriate organic solvent in a reaction mixture reduces the amount of water present in the reaction mixture and brings a high reaction rate and a high yield of the desired product. The N,N-dialkyl polyhydroxyalkyl amine can be widely used as a surfactant in various applications.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE: To obtain a composition for forming a closely adhering barrier for protecting the surface of a skin from a skin disease such as human or animal eczema, allergy, etc., by mixing a specific liquid carrier, a surfactant and a nontoxic polysiloxane emulsion in the composition. CONSTITUTION: This barrier composition contains a liquid carrier constituting 50-60wt.% of the composition (e.g.; deionized water), 1-5wt.% surfactant and 2-25wt.% nontoxic polysiloxane (e.g.; dimethylpolysiloxane) emulsion. The emulsion has &gt;0.2μm particle size. The dimethylpolysiloxane can contain 90.5-96wt.% siloxane and 4-7wt.% silicon dioxide. On removing the composition after application thereof, only a small amount of residue is left on the surface of the skin and does not irritate the skin by formulating a suitably balanced nonionic surfactant therewith.
The utility model relates to a sweet and crisp pilose antler chew tablet, which is used for the medicinal industry and is composed of a mixture, a pilose skin and a pilose body. The pilose body and the pilose skin are coated with mixture coating layers which make the pilose body and the pilose skin sweet and crisp. After pilose antler tablets are put in a container to be soaked in vinegar or iced vinegar, the pilose antler tablets are taken out and dried in shade. White sugar, essence, starch gum and food oil are made into the mixture, and the pilose antler tablets are put in the mixture to be mixed. The pilose antler tablets are shaped out finished products in a mould, and the pilose antler tablets are dried to sweet and crisp type. The pilose antler tablets can be chewed by a mouth after sealed and packaged. The utility model alters the defect that the existing pilose antler tablets can not be chewed by a mouth, and the application range of the utility model is wide. The manufacture process is conveniently realized, and the price is adaptable. The utility model is favorable for people&#39;s health.
The invention discloses an application of PMX-53 polypeptide in preparing a medicament for treating non-alcoholic steatohepatitis. After the treatment with PMX-53 inhibitor, the number of lipid droplets in the liver cells of NASH mice is reduced, the lipid droplets become small, and the liver fat becomes obviously reduced, as can be seen from H &amp; E and oil red O staining graphs (FIG. 3A); the quantitative PCR result shows that the expression of the fat synthesis related genes Srebf1, Acc and Fasn is remarkably reduced (figure 3B), and further confirmed by WB, the result of figure 3C shows that the fat synthesis related proteins Acc and Fasn are reduced in the liver tissue of the mouse; quantitative PCR and ELISA assays showed significant down-regulation of the expression of the inflammation-associated factors IL-6 and TNF-. alpha. (FIGS. 3D and E). These results show that the C5ar1 specific inhibitor PMX-53 treatment can reduce mouse non-alcoholic steatohepatitis, so that PMX-53 can be applied to the preparation of drugs for treating non-alcoholic steatohepatitis.
The preparation for controlling Pediculis humanis, in particular of hair, pubic and clothes lice and their nits is used for treatment and prevention in medicine. The preparation has very high biological activity, is easily applied, forms no sticking of the hairs and does not harm the skin and the hair. The preparation is applied in the form of lotions, balms, creams, sprays and others. It is in the form of aqueous emulsion of the oil/water type. The active components are O,O,O&#39;,O&#39;-tetramethyl-O-O&#39;-thiods-p-phenylene-bis(phosphorothioate) and cetyltrimethylammonium chloride. The emulsion also contains auxiliary substances - stabilizers, preservatives, antiseptics, softeners and aromatizers. 2 claims
PROBLEM TO BE SOLVED: To obtain the subject inhibitor mass-producible at a low cost by chemical synthesis by including a specific isocarbacyclin derivative as an active ingredient therein. SOLUTION: This inhibitor is obtained by including a 15R-isocarbacyclin derivative represented by formula I (R1 is a 1-6C hydrocarbon chain; R2 is H or a protecting group) as an active ingredient. For example, 15R-16-m- tolyl-17,18,19,20-tetranorisocarbacyclin (methyl ester) represented by formula II is preferred as the derivative. The inhibitor can be administered to a human or an animal by, e.g. intravenous injection, percutaneous injection or oral administration. The inhibitor can be prepared into a tablet, a powder, a solution, an emulsion, a capsule, a parenteral injection, etc. by including the isocarbacyclin derivative at &gt;=5 μM concentration and formulating the derivative together with a filter, an extender, a binder, a humectant, a disintegrator, a surface-active agent, a diluent, an excipient, etc.
PURPOSE: To directly and easily prepare nonoparticles of protein by preparing a first liquid phase of water and protein at a temp. lower than a protein solidifi cation temp., preparing an aq. second liquid phase at a temp. higher than the protein solidification temp. and mixing both. CONSTITUTION: The first liquid phase is prepd. from the protein, such as serum albumin and/or active substances, such as biological reagents and cosmetic components, in water or an aq. mixture at a low temp. below the solidification temp. of the protein and a surfactant is added to the liquid phase. Otherwise, the second liquid phase of the water or the aq. mixture contg. the biologically active substance is prepd. at a high temp. above the solidification temp. of the protein and the surfactant is added thereto. While the first liquid phase and the second liquid phase are gently stirred at a pH apart from the isoelectric point of the protein, both phases are mixed. Further, part or the whole of the water or the aq. mixture is removed if desired. The nanoparticles of &lt;=500 nm in size of a matrix type are thus easily obtd.
The invention provides compositions and methods for reducing one or more symptoms of disease by administering compositions comprising SipA. The invention&#39;s compositions and methods are particularly advantageous in reducing symptoms of diseases that are associated with overexpression of P-gp and/or p53. The invention&#39;s compositions and methods are useful in reducing cancer symptom and/or cancer multidrug resistance (MDR). The invention provides a method for reducing one or more symptoms of cancer in a mammalian subject in need thereof, comprising administering to said subject a composition comprising purified SipA. In one embodiment, said SipA is operably conjugated to a nanoparticle. In another embodiment, said cancer comprises cancer cells resistant to at least one cytotoxin.
PROBLEM TO BE SOLVED: To produce a new compound, having an excellent solubility, good stability even under weak acidic conditions, antimicrobial effects and useful as a cosmetic, a pharmaceutical preparation, an agricultural formulation, an animal drug formulation, a food, a feed, etc. SOLUTION: This zinc salt of L-ascorbic acid 2-phosphate and its hydrate salt. The compound is obtained by carrying out a chemical reaction of, e.g. a salt other than zinc of L-ascorbic acid 2-phosphate (e.g. Ap2 Mg3 when the L-ascorbic acid 2-phosphate is represented by Ap) as a raw material with an element such as Mg or substituting the element with zinc element by ion exchange, etc. The reaction can be combined with a purifying method. In the zinc salt of the L-ascorbic acid 2-phosphate and its hydrate salt, &gt;=95% based on the total charges of cations are preferably derived from zinc and &gt;=95% based on the total charges of anions are preferably derived from L-ascorbic acid 2-phosphate.
A method of treating diaper rash in a subject is provided. A method of treating athlete&#39;s foot in a subject is provided. A method of treating contact dermatitis in a subject is provided. A method of treating perspiration and body odor in a subject is provided. The method comprises administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the diaper rash, athlete&#39;s foot, contact dermatitis, or perspiration and body odor. Related preparations, kits, and devices are also provided.
The current study will be randomized control trial; data will be collected from Lahore Garrison Institute of Special Education. This study will be conducted with 32 participants equally divided into two groups. Inclusion criteria will be Children who diagnosed with Autism Spectrum Disorder (mild \&amp; moderate) according to Diagnostic and Statistical Manual of Mental Disorders, (DSM-5), Have an IQ 70 according to Stanford-Binet Intelligence Scales and be able to understand and follow instructions, Children whose age between 4 to 12 and All participants had to be able to sit and walk without support according to GMFCS. Exclusion criteria for the study include Children who will associate with attention deficit hyperactivity disorder signs, Upper limb musculoskeletal injuries, Visual or auditory impairments, Children who had received sensory integration therapy for \&gt; 3 months within the past 6 months and Children with speech delay, hearing impairment, or intellectual disability. SPM training will be given each child individually in the first group. In the second group techniques will be apply in a group therapy. The SPM training programme will apply for 10 months. Outcomes, including the Test of Movement Battery for Children, Quality of life scale will be use. Data analysis will be performed using SPSS version 23.00
PURPOSE: To obtain a therapeutic agent for neurofibromatosis (Recklinghausen&#39;s disease) by using 1α,24(R)-dihydroxycholecalciferol as an active ingredient. CONSTITUTION: This therapeutic agent for neurofibromatosis comprises containing 1α, 24(R)-dihydroxycholecalciferol, a kind of active form vitamin D3 &#39;s, as an active ingredient. This compound can directly suppress the growth of neurofibroma cells. It can be administered locally as well as systemically and prepared to the forms of external preparations (ointments, creams, lotions and tapes), injections, intranasal preparations and oral preparations. The therapeutic effective amount of the above compound is 100-0.1μg daily, preferably 50-0.1μg daily and these amounts are contained in one tablet in the case of tablets. And 100-0.1μg/g, preferably 50-0.5μg/g is contained in the case of the external preparations.
A patient room and bed management apparatus and system detects changes in a patient&#39;s status and updates the status of a room of a healthcare facility associated with the patient. The system may receive the patient status information from a remote system, such as a health information system used by a healthcare facility. The patient room and bed management system may determine one or more actions to be performed by a bed in the patient&#39;s room. The system may determine one or more actions to be performed by a caregiver or other staff person of the healthcare facility. The actions to be performed by the bed or staff person may be triggered by a change in status of the patient, the patient&#39;s bed, or the patient&#39;s room. The actions to be performed may be electronically communicated to the bed, to one or more remote displays, and/or to communication devices associated with staff persons of the healthcare facility. 
     The patient room and bed management apparatus and system may include a user interface module that is not mounted to the patient&#39;s bed. A list of actions to be performed by a staff person in the patient&#39;s room, the status of the patient, the status of the patient&#39;s room, and/or the status of the patient&#39;s bed, may be displayed and updated electronically at the user interface module. The user interface module may also provide bed controls that allow a staff person to initiate an electronically-controlled function of the bed from the user interface module.
A computer-based system and process are disclosed for reconstructing the internal electrical behavior of a patient&#39;s heart based partly or wholly on the patient&#39;s electrocardiogram (ECG). The output of the process may include, for example, a cardiac activation map, and/or a representation of transmembrane potentials over time. The process advantageously does not require any medical imaging of the patient, and does not require any special medical equipment. For example, the patient&#39;s activation map and transmembrane potentials may be reconstructed based solely on a preexisting or newly-obtained 12-lead cardiac ECG of the patient. The process makes use of a machine learning model, such as a neural network based model, trained with actual and/or simulated ECGs and intracardiac electrical data (typically transmembrane potentials) of many thousands of patients. Because an insufficient quantity of such data exists for actual patients, model training may be performed using ECGs and intracardiac electrical data obtained through computer simulations.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new method by which prophylaxis of viral infection can effectively be carried out even without using a vaccine.  &lt;P&gt;SOLUTION: The method for the prophylaxis of the viral infection comprises administering a large amount of vitamin C and arginine. A prophylactic agent for the viral infection comprises the vitamin C and arginine both coated with a coating. Thereby, the prophylaxis of an object against the viral infection can effectively be carried out. The required cost is remarkably lower than that of a prophylactic method using the vaccine and the risk of producing adverse effects is slight. No serious adverse effect is caused.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE: A composition containing catechin and garlic acid is provided to treat neurodegenerative diseases including Alzheimer&#39;s disease. CONSTITUTION: A composition for preventing and treating brain diseases contains Castaneae crenata inner skin extract. The extract is isolated using water, organic solvent, or mixture solvent thereof. The brain disease is Alzheimer&#39;s disease. A functional health food composition for treating brain disease contains Castaneae crenata inner skin extract. A composition for preventing and treating brain diseases contains polyphenol of garlic acid, catechin, or epicatechin or pharmaceutically acceptable salt thereof.